3411. What is the best adjuvant treatment for very young patients with medulloblastoma?. (April 2007) Authors: Clarke, James W; Hadziahmetovic, Mersiha; Tzou, Katherine; Lau, Ching C; Paulino, Arnold C; Grecula, John C; Montebello, Joseph F; Mayr, Nina A; Lo, Simon S Journal: Expert review of neurotherapeutics Issue: Volume 7:Number 4(2007) Page Start: 373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3412. What is the best drug-delivery approach for the acute treatment of migraine?. (March 2012) Authors: Tepper, Stewart J; Stillman, Mark J Journal: Expert review of neurotherapeutics Issue: Volume 12:Number 3(2012) Page Start: 253 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3413. What is the potential of neurostimulation in the treatment of motor symptoms in schizophrenia?. (2nd July 2020) Authors: Lefebvre, Stephanie; Pavlidou, Anastasia; Walther, Sebastian Journal: Expert review of neurotherapeutics Issue: Volume 20:Number 7(2020) Page Start: 697 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3414. What is the potential of paramagnetic rim lesions as diagnostic indicators in multiple sclerosis?. (3rd October 2022) Authors: Martire, Maria Sofia; Moiola, Lucia; Rocca, Maria Assunta; Filippi, Massimo; Absinta, Martina Journal: Expert review of neurotherapeutics Issue: Volume 22:Number 10(2022) Page Start: 829 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3415. What is the potential of statins in the treatment of depression?. (2nd April 2020) Authors: De Uribe Viloria, Nieves; Berk, Michael Journal: Expert review of neurotherapeutics Issue: Volume 20:Number 4(2020) Page Start: 307 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3416. What is the potential of virtual reality for post-stroke sensorimotor rehabilitation?. (3rd March 2020) Authors: Levin, Mindy F. Journal: Expert review of neurotherapeutics Issue: Volume 20:Number 3(2020) Page Start: 195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3417. What is the risk of aluminium as a neurotoxin?. (June 2014) Authors: Exley, Christopher Journal: Expert review of neurotherapeutics Issue: Volume 14:Number 6(2014) Page Start: 589 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3418. What is the risk of aluminium as a neurotoxin?. (June 2014) Authors: Exley, Christopher Journal: Expert review of neurotherapeutics Issue: Volume 14:Number 6(2014) Page Start: 589 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3419. What is the role of placebo in neurotherapeutics?. (2nd January 2022) Authors: Frisaldi, Elisa; Shaibani, Aziz; Trucco, Marco; Milano, Edoardo; Benedetti, Fabrizio Journal: Expert review of neurotherapeutics Issue: Volume 22:Number 1(2022) Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3420. What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?. (July 2015) Authors: Davis, Ian; Liu, Aimin Journal: Expert review of neurotherapeutics Issue: Volume 15:Number 7(2015) Page Start: 719 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗